Clinical Trials Browser

Phase NA × NSCLC × Erlotinib Hydrochloride × Clear all

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Phase NA Unknown

NSCLC